Hospital Pharmacy Collaboration Preserves Canadian Access to Pediatric Ciprofloxacin Suspension

Mohawk Medbuy Corporation reported on September 17, 2026, that members of its Pharmacy Pediatric Subcommittee helped preserve access to Canada’s only commercially available ciprofloxacin oral suspension after learning that discontinuation was planned. The development is most immediately relevant to hospital and institutional pharmacists, with downstream importance for community pharmacists supporting pediatric patients after discharge.

The subcommittee escalated the access concern through Canada’s Provincial/Territorial Drug Shortages Task Team and supplier channels. Mohawk Medbuy reports that the manufacturer subsequently decided to continue production. The organization did not identify that manufacturer in its article.

Health Canada’s Drug Product Database currently lists CIPRO oral suspension 500 mg/5 mL, DIN 02237514, as marketed. A ready-to-use suspension can be important for children who cannot swallow tablets; Mohawk Medbuy notes that alternatives may involve compounding, palatability and adherence challenges, intravenous therapy or delayed discharge.

Practice guidance for pharmacists

• Verify current wholesaler availability and local formulary status before promising supply to a patient or care team.
• Reserve available suspension for patients with a documented need for a liquid dosage form, following institutional stewardship policies.
• If compounding is considered, use an evidence-based formulation and document concentration, beyond-use date, storage and administration instructions.
• Reconcile the exact concentration and dose at transitions of care to reduce errors between commercial and compounded liquids.
• Report emerging supply constraints through established procurement and drug-shortage channels rather than assuming continued production guarantees uninterrupted availability.

The reversal demonstrates how coordinated hospital-pharmacy escalation can preserve access before a discontinuation becomes a patient-level shortage. Pharmacists should nevertheless continue routine supply surveillance because marketed status does not guarantee availability at every wholesaler or site.